Wegovy Symptoms: What the Label Says

A post about a difficult few days after a Wegovy change is not enough to identify the cause of headache or diarrhea in one person. Abdominal pain also needs individual assessment. It can, however, point readers to the right source to check first: the current official product information. The United States Wegovy label lists diarrhea and headache among its most common adverse reactions. It also lists abdominal pain^[1]. This explainer separates that label information from a diagnosis and from a personal dosing decision.

What the official Wegovy label lists

Wegovy contains semaglutide, which is covered in our semaglutide overview. The FDA-hosted prescribing information lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness, abdominal distension, reflux, and other reactions among the adverse reactions reported most commonly in trials^[1]. A listed reaction describes what was reported in the studied population. It does not establish that the medicine caused a particular symptom in a particular reader.

That distinction matters for an online report. Headache, diarrhea, and abdominal pain have many possible explanations, and the label cannot sort them for an individual. Nor can a comment thread determine whether a symptom is expected, whether it needs assessment, or whether a medicine should be changed. The product information is a safety reference, not a substitute for the clinician who prescribed it.

The label also should not be used to collapse different semaglutide products into one personal forecast. Wegovy has its own indications and safety wording, while other approved semaglutide products have separate labels. Our GLP-1 receptor agonist overview, Ozempic background, and semaglutide regulation notes provide related context, but none can interpret a particular symptom. The current label for the exact medicine is the relevant document for product-specific warnings, and a clinician can apply it to the person rather than to a general online description.

Why gastrointestinal symptoms deserve context

The Wegovy label says semaglutide delays gastric emptying and warns that gastrointestinal adverse reactions can sometimes be severe^[1]. It also describes postmarketing kidney injury reports in patients who had nausea, vomiting, or diarrhea that led to dehydration. This is a label warning about a possible safety pathway; it does not mean that every episode of diarrhea has that consequence.

The National Institute of Diabetes and Digestive and Kidney Diseases lists loose or watery stools, urgency, abdominal cramping or pain, nausea, dizziness, vomiting, fever, and bloody stools among symptoms that can accompany diarrhea. Its patient guidance says adults should seek medical help for diarrhea lasting more than two days, high fever, frequent vomiting, severe abdominal or rectal pain, bloody or black stools, or symptoms of dehydration^[2]. Those general thresholds apply to diarrhea as a symptom; they do not identify its cause.

What the label flags as urgent

The Wegovy prescribing information directs clinicians to watch for acute pancreatitis symptoms, including persistent or severe abdominal pain that may radiate to the back, with or without nausea or vomiting^[1]. It also carries warnings for serious allergic reactions, gallbladder disease, acute kidney injury from volume depletion, and severe gastrointestinal reactions. These are defined label warnings, not a conclusion about any story posted online.

If a person has symptoms described as severe, persistent, or accompanied by warning signs in the label or diarrhea guidance, the appropriate next step is prompt clinical assessment rather than crowd-sourcing a medication decision. The same principle applies to an unusually severe headache: the Wegovy label records headache as a common adverse reaction, but it cannot determine what any one headache represents.

Why a change in treatment does not prove cause

Timing can be useful information for a clinician, but it is not proof of causation. The Wegovy label notes that clinicians should monitor patients reporting reactions that could lead to volume depletion, especially during treatment initiation and escalation^[1]. That is a monitoring instruction for professionals. It is not a home protocol and it does not say that every symptom after a treatment change was caused by semaglutide.

Readers comparing products can also review the current semaglutide safety section and the site's regulation overview. Brand names, authorized uses, and label wording vary by market. The official information for the exact product and country is more reliable than assuming that a forum account maps directly to another person's prescription.

The practical boundary of this explainer

This article does not recommend a dose, a titration plan, a product switch, or stopping a medicine. It explains what the official Wegovy label says about reported reactions and red-flag symptom language. An online account can raise a useful question, but it cannot diagnose a medication reaction or establish that semaglutide caused the symptoms described. Readers looking for broader context can consult the Wegovy and semaglutide overview and the medicine regulation index, while using the current product information for exact warning language. It is designed to support a source-based conversation with a clinician.